Transoma Medical Enrolls First Patient in Clinical Study Comparing Use of External Recorders with Implantable Monitors to Track Recurrence of Atrial Fibrillation
9/23/2009 9:26:53 AM
ST. PAUL, Minn.--(BUSINESS WIRE)--Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced today the first enrollment and implant in the COMPLIANCE trial, a long-term study to compare external event recorders with implantable monitors in patients who have been prescribed catheter ablation therapy for atrial fibrillation (AF) at risk of post-procedure AF recurrence. Dr. Dhanunjaya Lakkireddy performed the first implant at the University of Kansas Medical Center, Kansas City, Kansas. Dr. Lakkireddy, director of the Center for Excellence in Atrial Fibrillation, Bloch Heart Rhythm Center, and associate editor of the Journal of Atrial Fibrillation, is the principal investigator for the clinical study. The company received FDA 510(k) marketing clearance for Sleuth AT, its next-generation product, in February 2009.
comments powered by